



Biotech Daily

Wednesday February 9, 2022

Daily news on ASX-listed biotechnology companies

Actinogen: Worldwide To Manage Xanamem Fragile X Trial

[ACTINOGEN MEDICAL](#)

Actinogen says it will pay Worldwide Clinical Trials \$13.6 million to manage its Xanax, 75-patient, phase II trial of Xanamem for Fragile X syndrome.

In 2021, Actinogen said that it had a letter-of-intent with the Durham, North Carolina-based Worldwide Clinical Trials for the trial and would pay \$944,724 “for start-up activities to enable prompt activation of sites” (BD: Nov 9, 2021).

At that time, the company said it had US Food and Drug Administration approval for its investigational new drug application for the patient phase II trial.

Today, Actinogen said the trial would study cognition, anxiety, sleep and behavioral patterns in male adolescents and young adults who had the full genetic features associated with Fragile X syndrome.

The company said the randomized, placebo-controlled, double-blind, 12-week trial of oral 5mg and 10mg Xanamem would be conducted in North America, Great Britain, Australia and New Zealand, with results expected in 2023.

The company said that Worldwide Clinical Trials had a work order, full-service contract worth \$13.6 million, in addition to the \$944,724 for start-up activities.

Actinogen managing-director, Dr Steven Gourlay said the company was “pleased to finalize a full-service contract with Worldwide Clinical Trials for the management of our phase II, Fragile X syndrome trial, the scope of which has recently been expanded to include a larger number of participants and with investigative sites across the US, UK and NZ, in addition to Australia”.

“There are currently no treatments approved anywhere in the world for [Fragile X] and the commencement of Actinogen’s key Xanax trial is another important step in our quest to help make a material difference to the quality of life for people and their families living with [Fragile X],” Dr Gourlay said.

Actinogen was unchanged at 11.5 cents with 3.8 million shares traded.